Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The firm develops drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano in 2007 and is headquartered in Purchase, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

- SHINE Alzheimer's Trial Expands to European Sites - - SEQUEL Alzheimer's Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active -

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®.

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, announced today that the Company's president and CEO, Lisa Ricciardi will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Neurology & Psychiatry Conference taking place in San Francisco from October 6-7, 2022.

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022.

Cognition Therapeutics Announces Participation in September Investment Conferences

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer's Disease Positive Preliminary Data for Dry AMD Program Presented at ARVO 2022 Proteomics Data from SPARC read out at AAIC

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Presented at Alzheimer's Association International Conference August 4, 2022 Presented at Alzheimer's Association International Conference August 4, 2022

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease Processes

- Analyses Demonstrate CT1812 Impact on Alzheimer's Disease Processes -

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer's Disease

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association -

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition's president and CEO will be presenting an update on the company's progress developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. A live and archived webcast can be accessed here as well as on the company's Events & Presentations webpage.

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

Taking place on June 9 at 10:00 a.m. ET Taking place on June 9 at 10:00 a.m. ET

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that Lisa Ricciardi, the Company's president and CEO and Mary Hamby, Ph.D., vice president of research, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously stated. The corrected release follows:

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that it will report financial results for the first quarter ended March 31, 2022 and provide a business update before the financial markets open on Tuesday, May 11, 2022.

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study for CT1812, the company's lead σ-2 receptor modulator, in patients with dry AMD.

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities' Neuro & Ophthalmology Conference taking place from April 27-28, 2022.

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that the company would be participating in Needham & Company's 21st Annual Virtual Healthcare Conference being held April 11-14, 2022. The Company's president and CEO, Lisa Ricciardi, will be providing a corporate update on Monday, April 11, 2022 from 3:00 – 3:40 p.m. ET.

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript

- Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer's disease enhanced by new DLB study and dry AMD program - - Conference call and live audio webcast scheduled for Wednesday, March 30 at 8:00 a.m. ET -

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer's disease and other neurodegenerative disorders. Specifically, data will be presented from the Phase 1b SNAP study (COG0104; NCT03522129) and an interim analysis from the Phase 2 SHINE study (COG0201; NCT03507790) in two posters at the upcoming AD/PD™ 2022: the 16th International Conference on Alzheimer's & Parkinson's Diseases.

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2022

Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics” Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics”

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

The stock price of Cognition Therapeutics Inc (NASDAQ: CGTX) increased by over 16% during intraday trading today. This is why it happened.

Cognition Therapeutics Stock (CGTX): Why The Price Surged Today

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company's 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.

News for Cognition Therapeutics Stock (CGTX)